Bosutinib (Bosulif) has received FDA approval for use in patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia who are resistant to or intolerant of other therapies, including imatinib. Bosutinib blocks the signal of the tyrosine kinase that promotes the development of abnormal and unhealthy granulocytes.
The angiogenesis inhibitor ziv-aflibercept (Zaltrap) has received approval from the FDA for use in combination with a FOLFIRI (folinic acid, fluorouracil, and irinotecan) chemotherapy regimen in adult patients with metastatic colorectal cancer. Ziv-aflibercept is indicated for persons whose tumors are resistant to or have progressed after treatment with oxaliplatin-containing chemotherapy.
Everolimus oral suspension tablets (Afinitor Disperz), a pediatric formulation of the drug, has received FDA approval. The formulation is the first pediatric-specific dosage form developed for the treatment of a tumor in pediatric patients. Afinitor Disperz is indicated for patients 12 months and older with subependymal giant cell astrocytoma (SEGA), a rare brain tumor.